Method From March 2016 all referrals to the Prince Charles Hospital were reviewed for
suitability for CURE-IT. Simultaneously, community providers were engaged and provided …

Background Although the availability of fully funded direct‐acting antivirals (DAAs) and the
eligibility of primary care providers (PCPs) to provide hepatitis C virus (HCV) have removed …

Background Australia is committed to eliminating the hepatitis C virus (HCV) by 2030.
Despite regulations in Australia that enable the prescription of subsidised direct acting …

Abstract Introduction: Hepatitis C HCV infection is a major cause of chronic liver disease and
death. In the EU, primary care is increasingly providing long-term care for people who inject …

Objectives Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has excellent
cure rates and minimal side effects. Despite the high burden of disease, strategies to …

Background A unique model of care was adopted in Australia following introduction of
universal subsidised direct‐acting antiviral (DAA) access in 2016 in order to encourage …

The evolution of management of hepatitis C virus (HCV) has seen a majority of patients
treated being regarded as cured. Despite this development, uptake of treatment remains low …

BACKGROUND & AIMS: A unique model of care was adopted in Australia following
introduction of universal subsidised direct-acting antiviral (DAA) access in 2016 in order to …

People with hepatitis C virus (HCV) are a marginalised population that may experience
discrimination in everyday contexts, including health‐care, due to the association of HCV …

Introduction The advent of direct acting antiviral therapy for hepatitis C virus (HCV) means
the elimination of HCV is possible but requires sustained effort to achieve. Between 2016 …